首页> 外文OA文献 >Once daily intravenous (IV) busulfan (Bu) containing preparative regimens for hematopoietic stem cell transplantation (HSCT): Low incidence of Hepatic Veno-Occlusive Disease (HVOD) and improved early survival in a single center’s experience

【2h】

Once daily intravenous (IV) busulfan (Bu) containing preparative regimens for hematopoietic stem cell transplantation (HSCT): Low incidence of Hepatic Veno-Occlusive Disease (HVOD) and improved early survival in a single center’s experience

机译：每天一次包含用于造血干细胞移植（HSCT）的制备方案的静脉注射白消安（Bu）：肝静脉阻塞性疾病（HVOD）的发生率低，并且单个中心的经验可以提高早期生存率

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
相似文献
相关主题

著录项

作者
Benn H.; Amin A.; Susan H.-C.; Kramek D.; Janbay N.; Randhawa D.; Nath R.;
展开▼
作者单位

展开▼
年度 2005
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
专利

1. Ultrasound in Hepatic Veno-occlusive Disease (HVOD) after Pediatric Hematopoietic Stem Cell Transplantation (HSCT): Comparison of Diagnostic Criteria Including the Pediatric Criteria of European Society for Blood and Marrow Transplantation (EBMT) [J] . Chung Heeyoung, Im Soo-Ah, Kim Seong-Koo Pediatric Hematology and Oncology . 2020,第1a4期

机译：儿科造血干细胞移植（HSCT）后肝静脉闭塞疾病（HVOD）中的超声：诊断标准的比较，包括欧洲血液和骨髓移植的儿科标准（EBMT）
2. Low incidence of hepatic veno-occlusive disease in pediatric patients undergoing hematopoietic stem cell transplantation attributed to a combination of intravenous heparin, oral glutamine, and ursodiol at a single transplant institution. [J] . Lakshminarayanan S, Sahdev I, Goyal M, Pediatric transplantation. . 2010,第5期

机译：接受造血干细胞移植的小儿患者肝静脉闭塞性疾病的发生率较低，这归因于在单个移植机构中静脉注射肝素，口服谷氨酰胺和熊糖二醇的组合。
3. Phase I and pharmacokinetic study of once-daily dosing of intravenously administered busulfan in the setting of a reduced-intensity preparative regimen and allogeneic hematopoietic stem cell transplantation as immunotherapy for renal cell carcinoma. [J] . Shaughnessy P, Alexander W, Tran H, Military Medicine: Official Journal of AMSUS, The Society of the Federal Health Agencies . 2006,第2期

机译：在降低强度的制备方案和同种异体造血干细胞移植作为肾细胞癌的免疫疗法的情况下，静脉注射白消安每天给药一次的第一阶段和药代动力学研究。
4. Retrospective analysis of survival and treatment related mortality following a myeloablative hematopoietic stem cell transplant in childhood acute lymphoblastic leukemia. [D] . Dasgupta, Sreejeta. 2010

机译：儿童急性淋巴细胞白血病清髓性造血干细胞移植后生存和治疗相关死亡率的回顾性分析。
5. Evaluation of Reversed Administration Order of Busulfan (BU) and Cyclophosphamide (CY) as Conditioning on Liver Toxicity in Allogenic Hematopoietic Stem Cell Transplantation (ALL-HSCT) [O] . Mani Ramzi, Nasrin Namdari, Shirin Haghighat, 2020

机译：评价叶列（BU）和环膦酰胺（CY）的逆转给药顺序作为分发性造血干细胞移植肝毒性的调理（全HSCT）
6. Intravenous versus oral busulfan as part of a busulfan/cyclophosphamide preparative regimen for allogeneic hematopoietic stem cell transplantation: Decreased incidence of hepatic venoocclusive disease (HVOD), HVOD-related mortality, and overall 100-day mortality [O] . Kashyap Ashwin, Wingard John, Cagnoni Pablo, 2002

机译：静脉内与口服白消安作为异体造血干细胞移植的白消安/环磷酰胺制备方案的一部分：肝静脉闭塞性疾病（HVOD）的发生率降低，与HVOD相关的死亡率以及100天总死亡率

Once daily intravenous (IV) busulfan (Bu) containing preparative regimens for hematopoietic stem cell transplantation (HSCT): Low incidence of Hepatic Veno-Occlusive Disease (HVOD) and improved early survival in a single center’s experience

著录项

相似文献

相关主题

期刊订阅